Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06193174 · ClinicalTrials.gov registry record · Phase 1
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT06193174: Clinical Trial Phase 1 study, sponsored by University of Alabama at Birmingham.
NCT06193174 is a Phase 1 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06193174, a Phase 1 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located.
Primary Outcome
Adverse events will be monitored and any changes in status will be recorded for each patient as outlined in CTCAE v4.0 reporting requirements.
Interventions
- DRUG C134 Re-Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2025-03-07 |
| Phase | Phase 1 |
Why NCT06193174 stopped before completion
NCT06193174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which C134 Re-Administration is the first listed.
NCT06193174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06193174 about?
NCT06193174 is a clinical study titled "Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)". The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located.
What is the current status of trial NCT06193174?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-06-21. Estimated completion is 2025-03-07.
What interventions are being tested in trial NCT06193174?
The interventions under investigation include: C134 Re-Administration (DRUG).
Who is sponsoring clinical trial NCT06193174?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06193174's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI